N/A N=6 Treatment

Low-dose UVA1 Radiation in Cutaneous Lupus Patients

Cutaneous Lupus Erythematosus

Bottom Line

View on ClinicalTrials.gov: NCT01776190 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2023

Primary outcome: Primary: Change in Cutaneous Lupus Disease Area and Severity Index (CLASI) Activity Score — -1 Units on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: UVA1 radiation treatment (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Ben Chong
Primary completion: Sep 2022

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Cutaneous Lupus Disease Area and Severity Index (CLASI) Activity Score	-1	—
SECONDARY Change in Cutaneous Lupus Disease Area and Severity Index (CLASI) Damage Score	—	—

Summary

The investigators are conducting an open-label clinical trial determining the effects of UVA1 phototherapy on cutaneous lupus (CLE) patients. Past research on systemic lupus (SLE) subjects indicates that this treatment is likely to be effective in treating cutaneous lupus with few side effects. The fact that most CLE patients are seen at dermatology clinics also increases the usefulness of this study because there is a large probability that phototherapy treatment will be accessible for many of the patients that stand to benefit from it.

Eligibility Criteria

Inclusion Criteria

You must be 18 years or older with a diagnosis of cutaneous lupus.
You must have at least two active areas of cutaneous lupus.
You will need to come in three days a week for a 10-week period.
You will need to participate in four physician visits and blood draws.

Exclusion Criteria

You do not have a diagnosis of cutaneous lupus.
You have less than two active areas of cutaneous lupus.
You are unable to come in three days a week for treatment for a 10-week period.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01776190). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.